(MedPage Today) -- Federal health officials said Monday they remain focused on lettuce from Taylor Farms as the source of a multistate outbreak of the diarrhea-causing parasite Cyclospora, despite inaccurate test results that the government briefly...
(MedPage Today) -- Treatment with investigational duvakitug appeared to improve remission rates among patients with ulcerative colitis and endoscopic response rates in those with Crohn's disease, results from two cohorts of the phase IIb RELIEVE...
(MedPage Today) -- Spouses of people with dementia had a higher risk of developing dementia themselves, a matched cohort study of nearly 1 million married people in Taiwan showed. Compared with unexposed spouses, both husbands and wives of dementia...
(MedPage Today) -- Having dismantled the U.S. Agency for International Development and decimated the CDC's global health capacities, the Trump administration has resorted to a blunt instrument to protect the American public from the Bundibugyo...
(MedPage Today) -- The market for compounded GLP-1 drugs remained robust despite the end of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, with many facilities adding ingredients like B vitamins and some operating...
Looming financial pressures in the healthcare sector, including cuts to Medicaid, are contributing to the rising rate of bankruptcies, according to the report by Gibbins Advisors.
About one in 10 physicians in a residency or fellowship program are sponsored under a J visa. Many training programs run longer than the new rule's four-year cap, thereby requiring students to apply for an Extension of Stay with the government.
Quarterly bankruptcy filings appear to be leveling out after years of volatility, which "is surprising considering the on-the-ground pressures we see operators facing every day," a Gibbins Advisors principal said.
Healthcare affordability is still the leading overall issue for voters heading into midterms, though another Trump administration talking point is gaining steam, according to a KFF survey report.
(MedPage Today) -- For respiratory syncytial virus (RSV) prevention, the long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated among infants at increased risk for severe disease through two RSV seasons, a randomized clinical...